Search

Your search keyword '"O'Connor, Sheila"' showing total 343 results
Start Over Author "O'Connor, Sheila"
343 results on '"O'Connor, Sheila"'

3. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma

Author

Martín-Garcia, David, Navarro, Alba, Valdés-Mas, Rafael, Clot, Guillem, Gutiérrez-Abril, Jesús, Prieto, Miriam, Ribera-Cortada, Inmaculada, Woroniecka, Renata, Rymkiewicz, Grzegorz, Bens, Susanne, de Leval, Laurence, Rosenwald, Andreas, Ferry, Judith A., Hsi, Eric D., Fu, Kai, Delabie, Jan, Weisenburger, Dennis, de Jong, Daphne, Climent, Fina, O'Connor, Sheila J., Swerdlow, Steven H., Torrents, David, Beltran, Sergi, Espinet, Blanca, González-Farré, Blanca, Veloza, Luis, Costa, Dolors, Matutes, Estella, Siebert, Reiner, Ott, German, Quintanilla-Martinez, Leticia, Jaffe, Elaine S., López-Otín, Carlos, Salaverria, Itziar, Puente, Xose S., Campo, Elias, and Beà, Sílvia

Published
2019
Full Text
View/download PDF

5. Protocol for a two-arm feasibility RCT to support postnatal maternal weight management and positive lifestyle behaviour in women from an ethnically diverse inner city population: the SWAN feasibility trial

Author

Bick, Debra, Taylor, Cath, Avery, Amanda, Bhavnani, Vanita, Craig, Victoria, Healey, Andy, Khazaezadeh, Nina, McMullen, Sarah, Oki, Bimpe, Oteng-Ntim, Eugene, O’Connor, Sheila, Poston, Lucilla, Seed, Paul, Roberts, Sarah, and Ussher, Michael

Published
2019
Full Text
View/download PDF

6. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Author

Cook, Gordon, Ashcroft, A John, Cairns, David A, Williams, Cathy D, Brown, Julia M, Cavenagh, Jamie D, Snowden, John A, Parrish, Christopher, Yong, Kwee, Cavet, Jim, Hunter, Hannah, Bird, Jenny M, Pratt, Guy, Chown, Sally, Heartin, Ernest, O'Connor, Sheila, Drayson, Mark T, Hockaday, Anna, and Morris, Treen C M

Published
2016
Full Text
View/download PDF

8. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

Author

Cook, Gordon, Williams, Cathy, Brown, Julia M, Cairns, David A, Cavenagh, Jamie, Snowden, John A, Ashcroft, A John, Fletcher, Marie, Parrish, Chris, Yong, Kwee, Cavet, Jim, Hunter, Hanna, Bird, Jenny M, Chalmers, Anna, O'Connor, Sheila, Drayson, Mark T, and Morris, Treen C M

Published
2014
Full Text
View/download PDF

10. Capacity and leadership development for wildlife conservation in sub-Saharan Africa: assessment of a programme linking training and mentorship

Author

Abu-Bakarr, Ibrahim, primary, Bakarr, Mohamed I., additional, Gelman, Nancy, additional, Johnny, Jonathan, additional, Kamanda, Philip Jimia, additional, Killian, Dan, additional, Lebbie, Aiah, additional, Murphy, Melanie, additional, Ntongho, Anne, additional, O'Connor, Sheila, additional, Sam-Mbomah, Edwin, additional, Thulla, Philip Foday Yamba, additional, and Wadsworth, Richard, additional

Published
2022
Full Text
View/download PDF

11. Additional file 1 of Cost-effectiveness of screening tools for identifying depression in early pregnancy: a decision tree model

Author

Heslin, Margaret, Jin, Huajie, Trevillion, Kylee, Ling, Xiaoxiao, Nath, Selina, Barrett, Barbara, Demilew, Jill, Ryan, Elizabeth G., O’Connor, Sheila, Sands, Polly, Milgrom, Jeannette, Bick, Debra, Stanley, Nicky, Hunter, Myra S., Howard, Louise M., and Byford, Sarah

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

16. Resumes

Author

Sterling, Eleanor J., Colquhoun, Ian C., Rigamonti, Marco M., White, Frances J., Balko, Elisabeth A., Fox, ElisaBeth A., Goodman, Steven M., O’Connor, Sheila, Langrand, Olivier, Macedonia, Joseph M., Jolly, Alison, Rasamimanana, Hantanirina R., Kinnaird, Margaret F., O’Brian, Timothy G., Crowley, Helen M., Harcourt, Caroline S., Gardner, Shea, Davidson, Jennifer M., Sauther, Michelle L., Sussman, Robert W., Rafidinarivo, Elie, Ganzhorn, Jörg U., Overdorff, Deborah J., Meyers, David M., Wright, Patricia C., Morland, Hilary Simons, Pereira, Michael E., Kappeler, Peter M., van Schaik, Carel P., Kappeler, Peter M., editor, and Ganzhorn, Jörg U., editor

Published
1993
Full Text
View/download PDF

19. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

Author

Cook, Gordon, Royle, Kara‐Louise, O'Connor, Sheila, Cairns, David A., Ashcroft, A. John, Williams, Cathy D., Hockaday, Anna, Cavenagh, Jamie D., Snowden, John A., Ademokun, Debo, Tholouli, Eleni, Andrews, Vivienne E., Jenner, Matthew, Parrish, Christopher, Yong, Kwee, Cavet, Jim, Hunter, Hannah, Bird, Jenny M., Pratt, Guy, Drayson, Mark T., Brown, Julia M., and Morris, Treen C. M.

Subjects
Male, relapsed multiple myeloma, overall survival, Kaplan-Meier Estimate, Transplantation, Autologous, cytogenetics, Disease-Free Survival, Translocation, Genetic, Humans, Multicenter Studies as Topic, duration of response, Antineoplastic Agents, Alkylating, Cyclophosphamide, In Situ Hybridization, Fluorescence, Aged, Proportional Hazards Models, Randomized Controlled Trials as Topic, Sequence Deletion, Chromosomes, Human, Pair 14, Salvage Therapy, Haematological Malignancy, Hematopoietic Stem Cell Transplantation, Middle Aged, Combined Modality Therapy, Clinical Trials, Phase III as Topic, salvage ASCT, Female, Chromosomes, Human, Pair 4, Multiple Myeloma, Chromosomes, Human, Pair 16, Research Paper, Chromosomes, Human, Pair 17, Follow-Up Studies
Abstract

Summary The Myeloma X trial (ISCRTN60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation (ASCT) or weekly cyclophosphamide following re‐induction therapy. Cytogenetic analysis performed at trial registration defined t(4;14), t(14;16) and del(17p) as high‐risk. The effect of cytogenetics on time to progression (TTP) and overall survival was investigated. At 76 months median follow‐up, ASCT improved TTP compared to cyclophosphamide (19 months (95% confidence interval [95% CI] 16–26) vs. 11 months (9–12), hazard ratio [HR]: 0·40, 95% CI: 0·29–0·56, P

Published
2019

20. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

Author

Rawstron, Andy C., Bennett, Fiona L., O'Connor, Sheila J.M., Kwok, Marwan, Fenton, James A.L., Plummer, Marieth, de Tute, Ruth, Owen, Roger C., Richards, Stephen J., Jack, Andrew S., and Hillmen, Peter

Subjects
Lymphocytosis -- Risk factors, Chronic lymphocytic leukemia -- Diagnosis, Chronic lymphocytic leukemia -- Risk factors, Chronic lymphocytic leukemia -- Causes of, Chronic lymphocytic leukemia -- Care and treatment
Abstract

A study attempts to examine the relationship between monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Results conclude that a biological relation exists between CLL-phenotype MBL and CLL.

Published
2008

24. Lifestyle information and access to a commercial weight management group to promote maternal postnatal weight management and positive lifestyle behaviour: the SWAN feasibility RCT

Author

Bick, Debra, primary, Taylor, Cath, additional, Bhavnani, Vanita, additional, Healey, Andy, additional, Seed, Paul, additional, Roberts, Sarah, additional, Zasada, Magdalena, additional, Avery, Amanda, additional, Craig, Victoria, additional, Khazaezadah, Nina, additional, McMullen, Sarah, additional, O’Connor, Sheila, additional, Oki, Bimpe, additional, Oteng-Ntim, Eugene, additional, Poston, Lucilla, additional, and Ussher, Michael, additional

Published
2020
Full Text
View/download PDF

26. Guidance for reporting the interpretation of cytogenomic test results in haematological neoplasms

Author

Rack, Katrina, primary, van den Berg, Eva, additional, Haferlach, Claudia, additional, Beverloo, Berna, additional, Espinet, Blanca, additional, Foot, Nicola, additional, Martin, Kate, additional, O'Connor, Sheila, additional, Schoumans, Jacqueline, additional, Talley, Polly, additional, Stioui, Sabine, additional, Zemanova, Zuzana, additional, Luquet, Isabelle, additional, and Hastings, Ros, additional

Published
2019
Full Text
View/download PDF

30. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

Author

Davies, Faith E., Dring, Ann M., Li, Cheng, Rawstron, Andrew C., Shammas, Masood A., O'Connor, Sheila M., Fenton, James A.L., Hideshima, Teru, Chauhan, Dharminder, Tai, Isabella T., Robinson, Elizabeth, Auclair, Daniel, Rees, Karen, Gonzalez, David, Ashcroft, A. John, Dasgupta, Ranjit, Mitsiades, Constantine, Mitsiades, Nicholas, Chen, Lan B., Wong, Wing H., Munshi, Nikhil C., Morgan, Gareth J., and Anderson, Kenneth C.

Published
2003
Full Text
View/download PDF

37. Unusual presentation of common acute lymphoblastic leukemia antigen-positive extramedullary disease in childhood: two patients with isolated masseter muscle involvement

Author

Wimperis, Jennifer Z., Brandt, Laura J., O'Connor, Sheila, Marcus, Robert, and Broadbent, Valerie

Subjects
Face Muscles -- Abnormalities, Lymphoblastic leukemia in children -- Diagnosis, Health
Abstract

Two children with unusual extramedullary common acute lymphoblastic leukemia antigen (CALLA)-positive (CD10) disease are reported. Isolated masseter infiltration with CD10/CD19-positive lymphoblasts was present in both patients with no other evidence of disease. One child had relapse of common acute lymphoblastic leukemia, and the other had primary disease. Disease may have spread from lymph nodes overlying the masseter muscle. Immunophenotyping and immunogenotyping provided a rapid and accurate diagnosis for both children. Cancer 1992; 70:897-901.

Published
1992

38. Accuracy of the Whooley questions and the Edinburgh Postnatal Depression Scale in identifying depression and other mental disorders in early pregnancy

Author

Howard, Louise Michele, primary, Ryan, Elizabeth G., additional, Trevillion, Kylee, additional, Anderson, Fraser, additional, Bick, Debra, additional, Bye, Amanda, additional, Byford, Sarah, additional, O'Connor, Sheila, additional, Sands, Polly, additional, Demilew, Jill, additional, Milgrom, Jeannette, additional, and Pickles, Andrew, additional

Published
2018
Full Text
View/download PDF

40. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

Author

Ross, Fiona M, Avet-Loiseau, Hervé, Ameye, Geneviève, Gutiérrez, Norma C, Liebisch, Peter, O'Connor, Sheila, Dalva, Klara, Fabris, Sonia, Testi, Adele M, Jarosova, Marie, Hodkinson, Clare, Collin, Anna, Kerndrup, Gitte, Kuglik, Petr, Ladon, Dariusz, Bernasconi, Paolo, Maes, Brigitte, Zemanova, Zuzana, Michalova, Kyra, Michaux, Lucienne, Neben, Kai, Hermansen, N Emil U, Rack, Katrina, Rocci, Alberto, Protheroe, Rebecca, Chiecchio, Laura, Poirel, Hélène, Sonneveld, Pieter, Nyegaard, Mette, Johnsen, Hans E, the European Myeloma Network, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Centre de génétique médicale UCL, UCL - (SLuc) Service d'hématologie, and Hematology

Subjects
medicine.medical_specialty, MEDLINE, Bioinformatics, 03 medical and health sciences, Prospective analysis, 0302 clinical medicine, Clinical report, Internal medicine, medicine, Humans, In Situ Hybridization, Fluorescence, Multiple myeloma, 030304 developmental biology, 0303 health sciences, Hematology, medicine.diagnostic_test, business.industry, Network on, medicine.disease, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, %22">Fish , Original Articles and Brief Reports, Multiple Myeloma, business, Fluorescence in situ hybridization
Abstract

The European Myeloma Network has organized two workshops on fluorescence in situ hybridization in multiple myeloma. The first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise in which 21 laboratories analysed diagnostic cases of purified plasma cells for recurrent abnormalities. The summary report was discussed at the EHA Myeloma Scientific Working Group Meeting 2010. During the quality control exercise there was acceptable agreement on more than 1000 tests. The conclusions from the collaboration were that the primary clinical applications for FISH analysis were for newly diagnosed cases of MM or frank relapse cases. A range of technical recommendations included: 1) Material should be part of the first draw of the aspirate; 2) Samples should be sent at suitable times that allow for the lengthy processing; 3) Most importantly PCs must be purified or specifically identified; 4) Positive cut-off levels should be the relatively conservative, 10% for fusion or break-apart probes and 20% for numerical abnormalities; 5) Informative probes should be combined to best effect; 6) In specialist laboratories a single experienced analyst is considered adequate; 7) At least 100 PC should be scored; 8) Essential abnormalities to test for are t(4;14), t(14;16) and 17p13 deletions; 9) Suitable commercial probes are available for clinically relevant abnormalities; 10) The clinical report should be expressed clearly and must state the percentage of PC involved and method used for identification; 11) A retrospective European based FISH data bank linked to clinical data should be generated and 12) Prospective analysis should be centralized for upcoming trials based on the recommendations. EMN aims to build on these recommendations to establish standards for a common European database to define subgroups with prognostic significance. ispartof: Haematologica vol:97 issue:8 pages:1272-1277 ispartof: location:Italy status: published

Published
2012

43. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial.

Author

Parrish, Christopher, Cook, Gordon, Andrews, Vivienne E., Jenner, Matthew, Yong, Kwee, Cavet, Jim, Hunter, Hannah, Bird, Jenny M., Pratt, Guy, Drayson, Mark T., Morris, Treen C. M., Royle, Kara‐Louise, Cairns, David A., Hockaday, Anna, Brown, Julia M., O'Connor, Sheila, Ashcroft, A. John, Williams, Cathy D., Cavenagh, Jamie D., and Snowden, John A.

Subjects
MULTIPLE myeloma, STEM cell transplantation, LIKELIHOOD ratio tests
Abstract

Summary: The Myeloma X trial (ISCRTN60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation (ASCT) or weekly cyclophosphamide following re‐induction therapy. Cytogenetic analysis performed at trial registration defined t(4;14), t(14;16) and del(17p) as high‐risk. The effect of cytogenetics on time to progression (TTP) and overall survival was investigated. At 76 months median follow‐up, ASCT improved TTP compared to cyclophosphamide (19 months (95% confidence interval [95% CI] 16–26) vs. 11 months (9–12), hazard ratio [HR]: 0·40, 95% CI: 0·29–0·56, P < 0·001), on which the presence of any single high‐risk lesion had a detrimental impact [likelihood ratio test (LRT): P = 0·011]. ASCT also improved OS [67 months (95% CI 59‐not reached) vs. 55 months (44–67), HR: 0·64, 95% CI: 0·42–0·99, P = 0·0435], with evidence of a detrimental impact with MYC rearrangement (LRT: P = 0·021). Twenty‐one (24·7%) cyclophosphamide patients received an ASCT post‐trial, median OS was not reached (95% CI: 39‐not reached) for these participants compared to 31 months (22–39), in those who did not receive a post‐trial ASCT. The analysis further supports the benefit of salvage ASCT, which may still be beneficial after second relapse in surviving patients. There is evidence that this benefit reduces in cytogenetic high‐risk patients, highlighting the need for targeted study in this patient group. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

45. Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

Author

Ashcroft, John, primary, Cairns, David A, additional, Williams, Cathy, additional, Hockaday, A, additional, Cavenagh, J. D., additional, Snowden, John A, additional, Parrish, Christopher, additional, Yong, Kwee L, additional, Cavet, Jim, additional, Hunter, Hannah, additional, Bird, Jennifer, additional, Pratt, Guy, additional, Chown, Sally, additional, Heartin, Earnest, additional, O'Connor, Sheila J.M., additional, Brown, Julia, additional, Morris, Curly, additional, and Cook, Gordon, additional

Published
2015
Full Text
View/download PDF

46. A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Author

Cook, Gordon, primary, Williams, Cathy, additional, Cairns, David A, additional, Hockaday, Anna, additional, Cavenagh, Jamie, additional, Snowden, John A, additional, Parrish, Christopher, additional, Yong, Kwee L, additional, Cavet, Jim, additional, Hunter, Hannah, additional, Bird, Jennifer, additional, Pratt, Guy, additional, Chown, Sally, additional, Heartin, Earnest, additional, O'Connor, Sheila J.M., additional, Ashcroft, John, additional, Brown, Julia, additional, and Morris, Curly, additional

Published
2015
Full Text
View/download PDF

47. CCND2and CCND3hijack immunoglobulin light-chain enhancers in cyclin D1−mantle cell lymphoma

Author

Martín-Garcia, David, Navarro, Alba, Valdés-Mas, Rafael, Clot, Guillem, Gutiérrez-Abril, Jesús, Prieto, Miriam, Ribera-Cortada, Inmaculada, Woroniecka, Renata, Rymkiewicz, Grzegorz, Bens, Susanne, de Leval, Laurence, Rosenwald, Andreas, Ferry, Judith A., Hsi, Eric D., Fu, Kai, Delabie, Jan, Weisenburger, Dennis, de Jong, Daphne, Climent, Fina, O'Connor, Sheila J., Swerdlow, Steven H., Torrents, David, Beltran, Sergi, Espinet, Blanca, González-Farré, Blanca, Veloza, Luis, Costa, Dolors, Matutes, Estella, Siebert, Reiner, Ott, German, Quintanilla-Martinez, Leticia, Jaffe, Elaine S., López-Otín, Carlos, Salaverria, Itziar, Puente, Xose S., Campo, Elias, and Beà, Sílvia

Abstract

Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation resulting in overexpression of cyclin D1. However, a small subset of cyclin D1−MCL has been recognized, and approximately one-half of them harbor CCND2translocations while the primary event in cyclin D1−/D2−MCL remains elusive. To identify other potential mechanisms driving MCL pathogenesis, we investigated 56 cyclin D1−/SOX11+MCL by fluorescence in situ hybridization (FISH), whole-genome/exome sequencing, and gene-expression and copy-number arrays. FISH with break-apart probes identified CCND2rearrangements in 39 cases (70%) but not CCND3rearrangements. We analyzed 3 of these negative cases by whole-genome/exome sequencing and identified IGK (n = 2) and IGL (n = 1) enhancer hijackings near CCND3that were associated with cyclin D3 overexpression. By specific FISH probes, including the IGK enhancer region, we detected 10 additional cryptic IGK juxtapositions to CCND3(6 cases) and CCND2(4 cases) in MCL that overexpressed, respectively, these cyclins. A minor subset of 4 cyclin D1−MCL cases lacked cyclin D rearrangements and showed upregulation of CCNE1and CCNE2.These cases had blastoid morphology, high genomic complexity, and CDKN2Aand RB1deletions. Both genomic and gene-expression profiles of cyclin D1−MCL cases were indistinguishable from cyclin D1+MCL. In conclusion, virtually all cyclin D1−MCLs carry CCND2/CCND3rearrangements with immunoglobulin genes, including a novel IGK/L enhancer hijacking mechanism. A subset of cyclin D1−/D2−/D3−MCL with aggressive features has cyclin E dysregulation. Specific FISH probes may allow the molecular identification and diagnosis of cyclin D1−MCL.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results